Investor Relations

Investor Relations

Corporate Profile

Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc. (“Lantheus”), which is a global leader in the development, distribution and commercialization of innovative diagnostic image agents and products. For 60 years, Lantheus has been dedicated to creating and providing pioneering medical imaging solutions to improve the treatment of human disease. Our agents and products assist physicians in the diagnosis of conditions affecting the heart, brain, lungs and other organs using echocardiography and nuclear imaging technologies.


NASDAQ | LNTH (Common Stock)

$8.28 + 0.39
Stock chart for: LNTH.O.  Currently trading at $8.28 with a 52 week high of $10.10 and a 52 week low of $1.76.
Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent News

09/22/16Lantheus to Present New Data at the ASNC Annual Scientific Session on the Novel PET Cardiac Imaging Agent Flurpiridaz F 18 in Patients with Suspected Heart Disease Undergoing Exercise Stress Testing
09/08/16Lantheus Holdings, Inc. Announces Public Offering of 5,200,000 Shares of Common Stock
08/24/16Lantheus Holdings, Inc. to Present at Upcoming Investor Conferences
08/11/16Lantheus Holdings Announces Divestiture of Its Australian Radiopharmacy Servicing Business and Entry into Long-Term Supply and Distribution Agreement

Upcoming Events

There are currently no events scheduled.

Receive E-mail Alerts

Sign up to receive e-mail alerts whenever Lantheus Holdings, Inc. posts new information to the site. Just enter your e-mail address and click Submit.